Drug:
Reaction: PRODUCT USE ISSUE
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25112126 |
BE |
14 | 2 |
Abdominal pain upper, Product use issue, Overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 202 | 25112127 |
BE |
2 | |
Somnolence, Vomiting, Intentional self-injury, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 203 | 25112155 |
CN |
75 | 2 |
Hypoglycaemia, Product use issue, |
||||
LINAGLIPTIN, INSULIN DEGLUDEC, |
||||
| 204 | 25112190 |
BE |
14 | 2 |
Abdominal pain upper, Overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 205 | 25112218 |
BE |
15 | 2 |
Vomiting, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 206 | 25112310 |
US |
1 | |
Feeling abnormal, Product use issue, |
||||
BRIVARACETAM, |
||||
| 207 | 25112313 |
US |
70 | 2 |
Trigeminal nerve disorder, Gait disturbance, Memory impairment, Overdose, Product use issue, |
||||
BRIVARACETAM, |
||||
| 208 | 25112351 |
US |
1 | |
Product use issue, |
||||
BRIVARACETAM, |
||||
| 209 | 25112426 |
US |
38 | 1 |
Seizure, Aggression, Somnolence, Fatigue, Hunger, Feeling abnormal, Constipation, Head injury, Wrong technique in product usage process, Incorrect dose administered, Product use issue, |
||||
BRIVARACETAM, BRIVARACETAM, TAURINE, |
||||
| 210 | 25112612 |
US |
17 | 2 |
Haematuria, Pain, Product use issue, |
||||
SPARSENTAN, |
||||
| 211 | 25112639 |
US |
1 | |
Product use issue, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 212 | 25112645 |
US |
30 | 2 |
Product use issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 213 | 25112649 |
US |
2 | |
Product dose omission issue, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 214 | 25112656 |
US |
2 | |
Musculoskeletal discomfort, Fungal infection, Psoriasis, Product use issue, |
||||
BIMEKIZUMAB, ERGOCALCIFEROL, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, LISINOPRIL AND HYDROCHLOROTHIAZIDE, LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, ROSUVASTATIN CALCIUM, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, ESTRADIOL, |
||||
| 215 | 25112688 |
US |
2 | |
Adverse drug reaction, Product dose omission issue, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 216 | 25112693 |
GB |
11 | 2 |
Pyrexia, Paronychia, Paronychia, Off label use, Product use in unapproved indication, Product use issue, Product use issue, |
||||
BINIMETINIB, BINIMETINIB, |
||||
| 217 | 25112730 |
US |
56 | 2 |
Chest pain, Headache, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 218 | 25112740 |
US |
2 | |
Fatigue, Oropharyngeal pain, Dysphonia, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 219 | 25112741 |
US |
2 | |
Weight increased, Product use issue, |
||||
BIMEKIZUMAB, PREDNISONE, |
||||
| 220 | 25112771 |
US |
||
Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 221 | 25112989 |
US |
2 | |
Product use issue, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 222 | 25113137 |
US |
70 | 1 |
Product use issue, Asthenia, |
||||
LENALIDOMIDE, |
||||
| 223 | 25113285 |
US |
2 | |
Illness, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 224 | 25113438 |
US |
2 | |
Menometrorrhagia, Implant site scar, Complication associated with device, Product use issue, |
||||
ETONOGESTREL, |
||||
| 225 | 25113443 |
CA |
2 | |
Exposure during pregnancy, Product use issue, Infusion related reaction, Intentional product misuse, Off label use, Overdose, Pain, Prescribed overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, INFLIXIMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ABACAVIR SULFATE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, BUPROPION HYDROCHLORIDE, BUPROPION, BUPROPION HYDROCHLORIDE, BUPROPION, CLONIDINE, CYCLOBENZAPRINE, CYCLOBENZAPRINE, MEPERIDINE HYDROCHLORIDE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUCONAZOLE, GABAPENTIN, ADALIMUMAB, ADALIMUMAB, HYDROMORPHONE HYDROCHLORIDE, KETOPROFEN, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE, MONTELUKAST SODIUM, MONTELUKAST, MONTELUKAST SODIUM, MONTELUKAST, MORPHINE SULFATE, MORPHINE SULFATE, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ABATACEPT, ABATACEPT, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PROGESTERONE, PROGESTERONE, QUETIAPINE FUMARATE, QUETIAPINE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, TEMAZEPAM, RITUXIMAB, RITUXIMAB, ALBUTEROL SULFATE, ALBUTEROL, SENNA LEAF, SENNA LEAF, SENNOSIDES, STANDARDIZED SENNA CONCENTRATE, STANDARDIZED SENNA CONCENTRATE, TEMAZEPAM, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ALBUTEROL SULFATE, VITAMIN C, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 226 | 25113450 |
DE |
41 | 2 |
Malignant neoplasm progression, Immune-mediated thyroiditis, Toxicity to various agents, Product use issue, Immune-mediated lung disease, Autoimmune thyroiditis, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, CISPLATIN, CISPLATIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, |
||||
| 227 | 25113504 |
US |
2 | |
Product use issue, Drug ineffective, |
||||
TESTOSTERONE, TESTOSTERONE, |
||||
| 228 | 25113587 |
US |
1 | |
Product use issue, Sleep disorder, Impaired driving ability, Headache, |
||||
VORTIOXETINE, AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE, SPIRONOLACTONE, CARVEDILOL, APIXABAN, ALLOPURINOL, DIGOXIN, AMLODIPINE, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, BREXPIPRAZOLE, |
||||
| 229 | 25113687 |
JP |
54 | 1 |
Overdose, Product use issue, No adverse event, |
||||
MOLNUPIRAVIR, MOLNUPIRAVIR, |
||||
| 230 | 25113905 |
US |
15 | 1 |
Product use in unapproved indication, Product use issue, |
||||
SPARSENTAN, |
||||
| 231 | 25113940 |
US |
||
Dyspnoea, Vision blurred, Breath holding, Arthritis, Musculoskeletal discomfort, Product use issue, Device delivery system issue, Product dispensing issue, Product lot number issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 232 | 25114075 |
US |
77 | 1 |
Tardive dyskinesia, Product use issue, Off label use, Drug interaction, |
||||
DEUTETRABENAZINE, DEUTETRABENAZINE, BUPROPION HYDROCHLORIDE, |
||||
| 233 | 25114226 |
CA |
2 | |
Abdominal discomfort, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthropathy, Blister, Condition aggravated, Confusional state, Contraindicated product administered, Contusion, Discomfort, Duodenal ulcer perforation, Dyspnoea, Folliculitis, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Ill-defined disorder, Impaired healing, Infection, Infusion related reaction, Injury, Pericarditis, Rheumatoid arthritis, Systemic lupus erythematosus, Gastrointestinal disorder, Arthralgia, Hepatic enzyme increased, Fatigue, Hypersensitivity, Exposure during pregnancy, Pain, Pemphigus, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, ALENDRONATE SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, HYDROCORTISONE ACETATE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, APREPITANT, FOSAPREPITANT DIMEGLUMINE, FOLIC ACID, FOLIC ACID, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, SARILUMAB, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, SULFASALAZINE, SULFASALAZINE, METHOTREXATE, METHOTREXATE SODIUM, TOCILIZUMAB, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, ETANERCEPT, ALENDRONATE SODIUM, ADALIMUMAB, ADALIMUMAB-ADAZ, ABATACEPT, ABATACEPT, HYDROXYCHLOROQUINE SULFATE, RITUXIMAB, RITUXIMAB, RITUXIMAB, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, TOCILIZUMAB, |
||||
| 234 | 25114677 |
US |
53 | 1 |
Agitation, Product use issue, Drug ineffective, |
||||
DEUTETRABENAZINE, |
||||
| 235 | 25114838 |
2 | ||
Hospitalisation, Product use issue, |
||||
AMBRISENTAN, |
||||
| 236 | 25114859 |
CN |
62 | 1 |
Thrombocytopenia, Leukopenia, Myelosuppression, Haemoglobin abnormal, Product use issue, |
||||
IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, FLUOROURACIL, OXALIPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 237 | 25114920 |
DE |
2 | |
Seizure, Product use issue, |
||||
BRENTUXIMAB VEDOTIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DACARBAZINE, |
||||
| 238 | 25115286 |
US |
2 | |
Burning sensation, Product use issue, Intentional product use issue, |
||||
HYDROXYPROPYL CELLULOSE, |
||||
| 239 | 25115298 |
JP |
||
Diabetes mellitus, Product use issue, Off label use, |
||||
DAPRODUSTAT, |
||||
| 240 | 25109182 |
US |
63 | 2 |
Asthenia, Injection site discharge, Product use issue, Drug ineffective, Mobility decreased, Hypoaesthesia, Swelling face, Asthenia, Infusion site discharge, Product distribution issue, Product dose omission issue, Insurance issue, |
||||
DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 241 | 25109291 |
US |
||
Product use issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 242 | 25109412 |
US |
50 | |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 243 | 25109698 |
US |
63 | 2 |
Eye irritation, Product dose omission in error, Product quality issue, Product packaging quantity issue, Product use issue, Product complaint, |
||||
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE, |
||||
| 244 | 25109719 |
PT |
56 | 2 |
Death, Cholestasis, Compartment syndrome, Acute myeloid leukaemia, Neurotoxicity, Hyperferritinaemia, Blood creatine phosphokinase increased, Investigation abnormal, Vertigo, Ataxia, Vomiting, Off label use, Product use issue, |
||||
GILTERITINIB, GILTERITINIB, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, VORICONAZOLE, VORICONAZOLE, BISOPROLOL FUMARATE, DIGOXIN, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 245 | 25109739 |
FR |
14 | 1 |
Hypogammaglobulinaemia, Neutropenia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, OBINUTUZUMAB, METHYLPREDNISOLONE, PREDNISONE, PREDNISONE, PREDNISONE, DARATUMUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 246 | 25107720 |
US |
||
Aspartate aminotransferase increased, Product use issue, |
||||
BOSENTAN, |
||||
| 247 | 25107725 |
US |
||
Product dose omission issue, Product use issue, |
||||
BOSENTAN, |
||||
| 248 | 25108252 |
US |
||
Incorrect dose administered by device, Visual impairment, Product use issue, Wrong technique in device usage process, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 249 | 25108317 |
BE |
13 | 2 |
Nausea, Abdominal pain, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 250 | 25108318 |
BE |
14 | 2 |
Headache, Abdominal pain, Vertigo, Overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 251 | 25108527 |
BE |
||
Nausea, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 252 | 25108528 |
BE |
18 | 1 |
Somnolence, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DICLOFENAC, DICLOFENAC SODIUM, |
||||
| 253 | 25108535 |
BE |
||
Vomiting, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 254 | 25108816 |
US |
2 | |
Burns third degree, Therapy interrupted, Product use issue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, OXYGEN, 0XYGEN, MELOXICAM, TIOTROPIUM BROMIDE INHALATION SPRAY, AMLODIPINE BESYLATE, ESCITALOPRAM OXALATE, ESCITALOPRAM, TADALAFIL, ALBUTEROL SULFATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, FUROSEMIDE, GABAPENTIN, VALSARTAN, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, |
||||
| 255 | 25109130 |
US |
58 | 2 |
Central serous chorioretinopathy, Product use issue, Product use in unapproved indication, |
||||
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, MINOXIDIL, OIL, |
||||
| 256 | 25102677 |
US |
2 | |
Jaw disorder, Product use issue, Pain, |
||||
REPOTRECTINIB, |
||||
| 257 | 25102743 |
US |
||
Burning sensation, Product use issue, |
||||
SODIUM FLUORIDE, SODIUM FLUORIDE F 18, SODIUM FLUORIDE F-18, TOOTHPASTE, SODIUM FLUORIDE F18, CLEAR MINT, GEL TOOTHPASTE, POTASSIUM NITRATE AND SODIUM FLUORIDE, POTASSIUM NITRATE, SODIUM FLUORIDE, STANNOUS FLUORIDE, POTASSIUM NITRATE, |
||||
| 258 | 25102751 |
US |
||
Drug ineffective, Infection, Memory impairment, Intentional product misuse, Product use issue, Device delivery system issue, Incorrect dose administered by device, Emergency care, Cough, Personality disorder, Illness, Fatigue, Product dose omission issue, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 259 | 25102787 |
BE |
||
Abdominal pain upper, Overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 260 | 25102980 |
US |
17 | 2 |
Product use issue, |
||||
ISOTRETINOIN, |
||||
| 261 | 25103048 |
US |
75 | |
Product use issue, Wrong technique in product usage process, No adverse event, |
||||
BUDESONIDE, |
||||
| 262 | 25103085 |
MX |
44 | 2 |
Colitis, Nausea, Gastritis, Headache, Product use issue, |
||||
ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 263 | 25103093 |
CA |
||
Brain fog, Crohn^s disease, Eye discharge, Fatigue, Vision blurred, Rash pruritic, Rash, Therapeutic response shortened, Product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, COLESTIPOL HYDROCHLORIDE, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, |
||||
| 264 | 25103128 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, AMANTADINE, LINACLOTIDE, |
||||
| 265 | 25103139 |
FR |
10 | 1 |
Hypogammaglobulinaemia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, PREDNISONE, PREDNISONE, OBINUTUZUMAB, DARATUMUMAB, METHYLPREDNISOLONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 266 | 25103182 |
FR |
10 | 1 |
Hypogammaglobulinaemia, Vomiting, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, PREDNISONE, PREDNISONE, DARATUMUMAB, OBINUTUZUMAB, METHYLPREDNISOLONE, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 267 | 25103255 |
US |
1 | |
Underdose, Product use issue, Product use in unapproved indication, Chest pain, |
||||
FLUTICASONE PROPIONATE, |
||||
| 268 | 25103705 |
US |
30 | 1 |
Depression, Product availability issue, Product use issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE, |
||||
| 269 | 25103836 |
US |
2 | |
Drug ineffective, Inappropriate schedule of product administration, Product use issue, |
||||
DICLOFENAC SODIUM, |
||||
| 270 | 25104131 |
DE |
||
Blood creatinine increased, Cardiac arrest, Overdose, Product use issue, |
||||
RITUXIMAB, ETOPOSIDE, CARBOPLATIN, CYTARABINE, CISPLATIN, IFOSFAMIDE, MESNA, MESNA INJECTION, RAMIPRIL, METOPROLOL TARTRATE, METOPROLOL, ALLOPURINOL, ACYCLOVIR, ACYCLOVIR, FOLIC ACID, DIMENHYDRINATE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, ZOLEDRONIC ACID, LINEZOLID, MEROPENEM, METHIMAZOLE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 271 | 25104204 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 272 | 25104266 |
US |
2 | |
Product use issue, Product availability issue, |
||||
AZILSARTAN KAMEDOXOMIL, |
||||
| 273 | 25104304 |
US |
2 | |
Product use issue, Product availability issue, Product dose omission issue, |
||||
AZILSARTAN KAMEDOXOMIL, |
||||
| 274 | 25104473 |
US |
2 | |
Drug dependence, Product use issue, |
||||
OXYMETAZOLINE HYDROCHLORIDE, |
||||
| 275 | 25104531 |
US |
||
Product use issue, Incorrect dose administered, Product dose omission issue, Wheezing, Product prescribing issue, Wrong technique in device usage process, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 276 | 25104730 |
US |
15 | 2 |
Product use issue, Product prescribing issue, Product use in unapproved indication, |
||||
ESTRADIOL, |
||||
| 277 | 25105107 |
US |
63 | 2 |
Product use issue, |
||||
DASATINIB, INSULIN GLARGINE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, TIRZEPATIDE, |
||||
| 278 | 25105147 |
US |
31 | 2 |
Hereditary angioedema, Viral infection, Emotional disorder, Product use issue, |
||||
| 279 | 25105148 |
EU |
||
Drug abuse, Product use issue, Injection site pain, Injection site oedema, Pyrexia, Infective aneurysm, Vascular graft, Staphylococcal infection, |
||||
BUPRENORPHINE HYDROCHLORIDE, ALCOHOL, ETHYL ALCOHOL, ISOPROPYL ALCOHOL, |
||||
| 280 | 25105180 |
US |
1 | |
Gastroenteritis viral, Fatigue, Product use issue, |
||||
ICATIBANT ACETATE, ICATIBANT ACETATE, |
||||
| 281 | 25105302 |
US |
56 | 2 |
Emotional distress, Therapeutic response unexpected, Product use issue, |
||||
BREMELANOTIDE, PROGESTERONE, HYDROCHLOROTHIAZIDE, SPIRONOLACTONE, |
||||
| 282 | 25105472 |
US |
33 | 1 |
Abdominal pain upper, Off label use, Product use issue, |
||||
AZITHROMYCIN DIHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 283 | 25105483 |
US |
27 | 1 |
Seizure, Product use issue, |
||||
PERAMPANEL, |
||||
| 284 | 25105610 |
US |
2 | |
Arthritis, Product use issue, |
||||
BEMPEDOIC ACID, |
||||
| 285 | 25105952 |
US |
77 | 1 |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 286 | 25106112 |
2 | ||
Product use issue, |
||||
AMBRISENTAN, FUROSEMIDE, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, |
||||
| 287 | 25106237 |
SE |
20 | 2 |
Pregnancy with implant contraceptive, Unintended pregnancy, Abortion spontaneous, Vaginal haemorrhage, Product use issue, |
||||
ETONOGESTREL, |
||||
| 288 | 25106340 |
JP |
8 | 2 |
Interstitial lung disease, Product use issue, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 289 | 25106349 |
IT |
20 | 1 |
Thrombocytopenia, Product use issue, |
||||
LEVETIRACETAM, |
||||
| 290 | 25106560 |
US |
||
Gastrointestinal disorder, Product use issue, |
||||
ESOMEPRAZOLE MAGNESIUM, |
||||
| 291 | 25106600 |
US |
78 | 2 |
Rash, Device leakage, Product use issue, |
||||
FREMANEZUMAB-VFRM, |
||||
| 292 | 25106730 |
CA |
50 | 2 |
Abdominal pain, Extrapyramidal disorder, Migraine, Neovascularisation, Weight decreased, Paradoxical drug reaction, Anuria, Cough, Diarrhoea, Dyspepsia, Dyspnoea, Nausea, Drug ineffective, Treatment failure, Drug ineffective for unapproved indication, Off label use, Product use in unapproved indication, Product use issue, |
||||
ATENOLOL, NAPROXEN, NAPROXEN SODIUM, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROCHLORPERAZINE, PROCHLORPERAZINE, PROCHLORPERAZINE, CANDESARTAN, CANDESARTAN, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, ERENUMAB-AOOE, ERENUMAB-AOOE, AMLODIPINE BESYLATE, CLONIDINE, GABAPENTIN, GABAPENTIN, LAMOTRIGINE, RIZATRIPTAN BENZOATE, METOCLOPRAMIDE HYDROCHLORIDE, NIFEDIPINE, NIFEDIPINE, PREDNISONE, PREDNISONE, TOPIRAMATE, TOPIRAMATE, DIVALPROEX SODIUM, DIVALPROEX SODIUM, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, BOTULINUM TOXIN TYPE A, BOTULINUM TOXIN TYPE A, FROVATRIPTAN SUCCINATE, DIMENHYDRINATE, VALPROATE SODIUM, ATENOLOL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ALLOPURINOL, VALPROIC ACID, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, DIVALPROEX SODIUM, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, RIZATRIPTAN, ERENUMAB-AOOE, |
||||
| 293 | 25107035 |
JP |
82 | 1 |
Interstitial lung disease, Drug ineffective, Product use issue, |
||||
MOLNUPIRAVIR, MOLNUPIRAVIR, |
||||
| 294 | 25107050 |
US |
47 | 2 |
Device issue, Product use issue, Device defective, |
||||
ABATACEPT, |
||||
| 295 | 25107121 |
US |
1 | |
Death, Swelling, Paraesthesia, Peripheral swelling, Burning sensation, Product packaging difficult to open, Product use issue, Back pain, Diarrhoea, |
||||
IXAZOMIB, IXAZOMIB, LENALIDOMIDE, DARATUMUMAB, |
||||
| 296 | 25107128 |
DE |
71 | 1 |
Renal impairment, Blood creatine phosphokinase increased, Myalgia, Transaminases increased, Product use issue, Drug interaction, |
||||
DAROLUTAMIDE, ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM, |
||||
| 297 | 25107446 |
US |
||
Product use issue, |
||||
C1 ESTERASE INHIBITOR RECOMBINANT, LANADELUMAB-FLYO, |
||||
| 298 | 25097394 |
US |
65 | 2 |
Product use issue, |
||||
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, |
||||
| 299 | 25097592 |
US |
2 | |
Product use issue, Product distribution issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 300 | 25097618 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28